SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: Micah Lance who wrote (57939)9/7/2016 10:53:00 AM
From: Wallace Rivers  Respond to of 78688
 
It's a reversion to the mean, in an established mega-cap stock with a dividend. I haven't banged out numbers on it, this is more of a buy low, sell high thesis.
Plus, although Opdivo is certainly wounded, it isn't dead.
I already owned competitor MRK, whose Keytruda seems to be winning the pharmaceutical battle to this point. I purchased BMY in the 57s last week.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News